COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

H. Lee Moffitt Cancer Center and Research Institute

Status: Completed

Conditions: SARS-CoV2 Infection; Covid19

Treatments: Biological: mRNA-1273

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05054218

MCC-21536

Details and patient eligibility

About

Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose

Enrollment: 336 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age
• Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine study (a basic science study) MCC 21138 or who has completed the two mRNA-1273 vaccine series prior to March 31, 2021.
• Understands, agrees and is able to comply with the study procedures and provides written informed consent.
• Has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reactions to the vaccine or its excipients.
• Has not received more or less than 2 doses of mRNA-1273 vaccine

Exclusion criteria

• Participants who will not return for the third vaccine dose

Trial design

336 participants in 1 patient group

Participants who receive 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

Description:

Cancer patients who have already received their 1st and 2nd doses of mRNA-1273 SARS-CoV-2 vaccine will receive a 3rd dose of the vaccine. The volume of vaccine injected will be 0.5 mL, containing a 100-μg dose of mRNA-1273.

Treatment:

Biological: mRNA-1273